Kenvue Inc. (NYSE:KVUE) is included on our list of the best undervalued wide moat stocks. ISS Backs Kenvue (KVUE) Deal, Investors Debate Tylenol and Litigation Risks Kenvue Inc. (NYSE:KVUE) is looking to potentially reshape the consumer health landscape, as it received institutional support for its proposed merger with Kimberly-Clark. On January 16, 2026, Reuters reported that Institutional Shareholder Services (ISS), a proxy advisory firm, recommended that shareholders approve Kimberly-Clark’s $40 billi ...

Market Overview - The U.S. stock market experienced significant declines, with over 70.7% of U.S. issues falling on Tuesday, while only 26.4% advanced [2] - The Nasdaq Composite and S&P 500 dropped by 2.39% and 2.06% respectively, with the Dow and Russell 2000 also showing losses of 1.76% and 1.20% [3] Earnings Reports - Major earnings reports expected today include Johnson & Johnson, Charles Schwab, and Prologis, with a focus on regional banks reporting in both premarket and aftermarket sessions [5] - The S&P Regional Bank ETF ($KRE) is anticipated to be particularly responsive to these reports, having risen over 14% since its lows in November 2025 [6]

格隆汇1月21日｜强生(JNJ.US)：第四季度销售额为245.6亿美元，高于预期的241.5亿美元。预计2026财 年运营销售额为995亿至1005亿美元，高于预估的989亿美元。 ...

本文源自：金融界AI电报 强生(JNJ.N)预计2026财年运营销售额为995亿至1005亿美元，高于预估的989亿美元。 ...

Johnson & Johnson on Wednesday forecast 2026 sales and profit ahead of Wall Street estimates, even when including a hit of "hundreds of millions of dollars" from the drug pricing deal it signed with... ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

The healthcare company's forecast for 2026 tops Wall Street's expectations. ...

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) today announced results for fourth-quarter and full-year 2025. "2025 was a catapult year for Johnson & Johnson, fueled by the strongest portfolio and pipeline in our history,†said Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson. "Last year kicked off a new era of accelerated growth, driven by medical innovation that is transforming lives in our six key businesses: Oncology, Immunology, Neuros. ...

Market Overview - U.S. stock futures rose on Wednesday after a significant sell-off on Tuesday, with major benchmark indices showing positive movement [1] - The S&P 500 index experienced its worst session since October 2025, dropping over 2% due to heightened risk-off sentiment following President Trump's new trade stance towards Europe [1] Trade Relations - President Trump threatened European countries with additional tariffs starting February 1 if negotiations over Greenland control fail, with potential duties increasing to 25% from June [2] - European officials warned of possible retaliation that could impact up to 25% of U.S. exports to Europe, including services, and mentioned the possibility of reducing Treasury holdings [2] Economic Indicators - The 10-year Treasury bond yielded 4.27%, while the two-year bond was at 3.58% [3] - The CME Group's FedWatch tool indicates a 95% likelihood of the Federal Reserve maintaining current interest rates in January [3] Index Performance - Major indices showed slight gains in premarket trading on Wednesday: Dow Jones up 0.19%, S&P 500 up 0.27%, Nasdaq 100 up 0.23%, and Russell 2000 up 0.33% [4] - The SPDR S&P 500 ETF Trust (NYSE:SPY) increased by 0.24% to $679.18, while Invesco QQQ Trust ETF (NASDAQ:QQQ) rose by 0.14% to $608.93 [4] Company Focus - Johnson & Johnson (NYSE:JNJ) projected to report quarterly earnings of $2.46 per share on revenue of $24.16 billion, down 0.33% in premarket [8] - Netflix Inc. (NASDAQ:NFLX) fell 5.48% despite better-than-expected fourth-quarter results, projecting first-quarter revenue of $12.16 billion, slightly below consensus [7] - GameStop Corp. (NYSE:GME) rose 2.70% after CEO Ryan Cohen disclosed a purchase of 500,000 shares at an average price of approximately $21.12 per share [9] Analyst Insights - Professor Jeremy Siegel noted a significant market transition, with a shift from large-cap growth to small-cap and value stocks, indicating a 10% to 12% pullback in large-cap growth stocks relative to value [13] - Siegel highlighted that the economic backdrop remains supportive, with resilient growth data and stable labor markets, suggesting that small-cap stocks do not require high earnings growth to perform well [14][15] Upcoming Economic Data - Investors are awaiting the delayed report of October's construction spending and December's pending home sales data, scheduled for release at 10:00 a.m. ET [16] Commodities and Global Markets - Crude oil futures decreased by 1.18% to around $59.65 per barrel, while Gold Spot rose by 2.24% to approximately $4,870.22 per ounce [17] - Bitcoin (CRYPTO: BTC) traded 1.64% lower at $89,347.25 per coin [19]

2026 年 1 月， Johnson & Johnson MedTech 宣布，在美国市场正式推出 Arbrea Breast Simulator Surgeon App for Mentor 。该产品是一款面向整形外科医生的 移动端数字化咨询工具 ，可运行于平板和智能手机， 用于乳房手术（尤其是隆乳手术）的术前沟通与方案展示。 从定位上看，该应用并非手术器械或术中系统，而是服务于 医患沟通与决策前端 的数字工具，目标在于提 升咨询阶段的可视化程度与沟通效率。 3. 实时辅助医生与患者讨论 医生可在咨询过程中动态展示不同方案的潜在效果，支持更结构化的方案对比与讨论，而非单向讲解。 从 技术属性上看，该产品属于 数字健康与三维可视化软件 ，并未涉及术中导航或治疗决策。 # 了解 A rbrea （ 一 ） 功能与技术特点拆解 根据强生 MedTech 的公开说明，Arbrea 应用的核心功能集中在以下几个方面： 1. 快速生成个性化 3D 模拟结果 应用可在约 60 秒内 生成患者个性化的三维模拟效果，用于展示不同隆乳方案可能带来的外观变化。 2. 替代传统"物理尺码 + 图片库"的沟通方式 强生指出，目前多 ...